USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is expected to post its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $240.9880 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.41 by $0.19. The company had revenue of $226.20 million for the quarter, compared to analyst estimates of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $19.30 on Monday. USANA Health Sciences has a fifty-two week low of $16.60 and a fifty-two week high of $38.32. The firm has a 50-day simple moving average of $18.58 and a two-hundred day simple moving average of $19.73. The company has a market cap of $356.28 million, a P/E ratio of 35.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.77.

Insider Transactions at USANA Health Sciences

In other news, insider Joshua Foukas sold 4,461 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.82% of the stock is owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI increased its position in shares of USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after acquiring an additional 3,589 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in shares of USANA Health Sciences in the 3rd quarter valued at $120,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on USNA. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.